Corrigendum: Protein arginine methyltransferase 1 is a therapeutic vulnerability in multiple myeloma

Front Immunol. 2023 Nov 15:14:1334733. doi: 10.3389/fimmu.2023.1334733. eCollection 2023.

Hong Phuong Nguyen¹, Anh Quynh Le¹, Enze Liu^{2

3}, Annamaria Cesarano⁴, Francesco DiMeo⁴, Fabiana Perna⁴, Reuben Kapur¹, Brian A Walker^{2

3}, Ngoc Tung Tran¹

¹ Herman B Wells Center for Pediatric Research, Department of Pediatrics, Indiana School of Medicine, Indianapolis, IN, United States.
² Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, United States.
³ Center for Computational Biology and Bioinformatics, School of Medicine, Indiana University, Indianapolis, IN, United States.
⁴ Division of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, United States.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2023.1239614.].

Keywords: PRMT1; multiple myeloma; relapsed/refractory myeloma; targeted therapy; xenograft model.